Status:
COMPLETED
Catheter Ablation for Atrial Fibrillation in Preserved Ejection Fraction
Lead Sponsor:
University Hospital Heidelberg
Collaborating Sponsors:
Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Brief Summary
Atrial fibrillation (AF) displays high prevalence in heart failure with preserved ejection fraction (HF-PEF) and compromises prognosis of affected patients. This study aims to assess catheter ablation...
Eligibility Criteria
Inclusion
- Left ventricular ejection fraction ≥50%
- Scheduled for catheter ablation of AF
Exclusion
- Significant valvular heart disease
- Coronary artery disease with \>70% stenoses or necessary coronary Intervention at time of recruitment
- Coronary intervention 60 days before recruitment
- Coronary bypass surgery 90 days before recruitment
- Cardiomyopathy or cardiac storage disease (e.g. amyloidosis)
- Reduced left ventricular ejection fraction
- Pericardiac disease
- Significant pulmonary hypertension
- Chronic obstructive pulmonary disease with home-oxygen-therapy, oral steroids, hospitalization due to exacerbations during the last 12 months before recruitment, or suspected severe pulmonary condition based on clinical evaluation
- Other non-cardiac conditions associated with limited physical capacity (adipositas permagna, severe anemia)
- Pregnancy
- Other limitations for adequate performance of stress echocardiography (e.g. orthopedic reasons)
Key Trial Info
Start Date :
January 26 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2022
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT04317911
Start Date
January 26 2016
End Date
February 1 2022
Last Update
October 27 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Heidelberg, Department of Cardiology
Heidelberg, Germany